ASELAGE STEVE, Director, added 3,000 shares of BioCryst Pharmaceuticals, Inc. (BCRX) to its portfolio at the rate of $3.57 per share valuing $10,710 on May 22. The insider has now 5,000 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of BioCryst Pharmaceuticals, Inc. (BCRX) was $3.61. Currently, the 1st Resistance Point for this stock is $3.67, with a 2nd Resistance Point sitting at $3.74. Meanwhile, this company’s stock has a 1st Support Level at $3.54 and a 2nd Support Level at $3.47. BioCryst Pharmaceuticals, Inc. (BCRX) stock has lost $0.02, or -2.17%, in the past five days. In the last full month, these shares have lost -$0.18, or -4.75%. In the past three months, this stock’s price has fallen by -$5.08, or -58.46%. This year-to-date, BioCryst Pharmaceuticals, Inc. (BCRX) shares have lost -$4.46, or -55.27%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For BioCryst Pharmaceuticals, Inc. (BCRX) stock, 0% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 25% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 67% of long-term indicators suggest that this stock is a “ Sell .”
With 110,313 K shares outstanding, this company currently has a market capitalization of $393,817K. BioCryst Pharmaceuticals, Inc. (BCRX) generates $20,650 K in annual sales, amounting to annual net income of -$101,250 K. This stock has generated a 1-Year Total Return of -41.21%, a 3-Year Total Return of 21.96%, and a 5-year Total Return of -68.02%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, BioCryst Pharmaceuticals, Inc. (BCRX) reported earnings of -$0.28 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.27 per share, representing a -0.01 difference and -2.87% surprise. In the previous quarter ending in Dec-18, the reported earnings of -$0.25 represented a 0 difference from the consensus estimate calling for -$0.25 per share, which was a -0.87% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.31 per share. This estimate came from a total of 5 Wall Street Analysts. Of those market experts, the high estimate was -$0.25 and the low estimate was -$0.34. In the year-ago quarter, BioCryst Pharmaceuticals, Inc. (BCRX) generated per-share earnings of -$0.19. If the analysts are correct about the current quarter’s earnings, the growth will be -63.16% .
Turning our focus now to insider trading activity, there have been 8 purchases (53,250 shares in total) and 8 sale (57,750 shares in total) in the last 3 months. In the last 6 months, there have been 19 insider buys amounting to 117,624 shares and 18 insider sales amounting to 97,637 shares. In the past full year, 49 insider purchases were made (involving 390,313 shares) and 58 insider sell-offs equivalent to 422,576 shares.
Moving onto liquidity, BioCryst Pharmaceuticals, Inc. (BCRX) has a Current Ratio of 1.65, a Quick Ratio of 1.62 and a Cash Ratio of 1.53. Looking at this company’s capital structure, its Total Debt to Total Equity is 125.57, its Total Debt to Total Capital is 55.67, and its Total Debt to Total Assets is now 42.10. Looking even further ahead into the future, its Long-Term Debt to Equity is 57.02 and its Long-Term Debt to Total Capital is 25.28.